Tamarind Bio Raises $12M in Series A Funding to Scale AI Drug Discovery Platform
Biology has always been a wet lab sport. Pipettes, petri dishes, late nights staring at results that whisper more questions than answers. Then AI showed up with promises of speed. The problem was the plumbing. Running molecular models, spinning up compute, wiring together tools like AlphaFold or RFdiffusion was less science and more infrastructure wrestling. Brilliant scientists were stuck playing part time IT manager. That friction is exactly where Tamarind Bio decided to plant its flag. And like the spice the company borrows its name from, the flavor cuts through the noise.
San Francisco based Tamarind Bio just secured $13.6M in funding, including a $12M Series A led by Dimension Capital with participation from Y Combinator. Congratulations to Deniz Kavi, Co Founder and CEO of Tamarind Bio, and the team for turning a real lab level pain point into infrastructure that serious biotech players are already leaning on.
The origin story reads like many great startups. It started solving a problem for a single Stanford lab. No grand speeches about saving the world. Just a simple observation. Scientists should be designing molecules, not configuring GPUs. That small fix turned into something much bigger.
Today Tamarind Bio gives researchers a no code platform and API access to run 200+ AI and simulation models across protein engineering and molecular design. Antibodies. Nanobodies. Peptides. Enzymes. Small molecules. The whole molecular menu. Tools like AlphaFold, RFdiffusion, ProteinMPNN and GROMACS become accessible without forcing a bench scientist to become a machine learning engineer overnight.
And the market is responding. The platform now supports 8 of the top 20 pharmaceutical companies along with hundreds of biotechs and academic institutions. Tens of thousands of scientists are running models through Tamarind’s infrastructure. Customers include Bayer, Boehringer Ingelheim, Adimab, Mammoth Biosciences, and organizations tied to Flagship Pioneering. Not exactly a casual group chat.
Security and ownership matter when billion dollar drug programs are on the line, so Tamarind runs on a SOC 2 compliant cloud where customers keep ownership of their data, inputs, and outputs. The company handles the orchestration, the scaling, the compute gymnastics behind the curtain. Scientists stay focused on the biology.
Dimension Capital clearly sees where this is going. Nan Li and the team are betting on the same shift many insiders are watching unfold quietly. AI is not replacing the lab. It is becoming the operating layer around it.
Tamarind Bio is riding that wave with 700% growth over the past year, evolving from a tool for 1 lab into infrastructure used across the pharmaceutical ecosystem. When the picks and shovels of an industry start moving faster than the gold itself, the smart money pays attention.
